Marinus Pharmaceuticals Inc (MRNS) 14-day ATR is 0.54: This Stock is Set to Soar Above its Peers

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) open the trading on Wednesday, with a bit cautious approach as it glided -1.92% to $8.70, before settling in for the price of $8.87 at the close. Taking a more long-term approach, MRNS posted a 52-week range of $5.57-$11.26.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 176.17%. Meanwhile, its Annual Earning per share during the time was 6.04%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 10.11%. This publicly-traded company’s shares outstanding now amounts to $54.58 million, simultaneously with a float of $50.81 million. The organization now has a market capitalization sitting at $475.37 million. At the time of writing, stock’s 50-day Moving Average stood at $9.52, while the 200-day Moving Average is $8.59.

Marinus Pharmaceuticals Inc (MRNS) Ownership Facts and Figures

Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Marinus Pharmaceuticals Inc’s current insider ownership accounts for 7.01%, in contrast to 94.03% institutional ownership. According to the most recent insider trade that took place on Feb 20 ’24, this organization’s CHIEF COMMERCIAL OFFICER sold 2,153 shares at the rate of 9.56, making the entire transaction reach 20,583 in total value, affecting insider ownership by 60,308. Preceding that transaction, on Feb 20 ’24, Company’s SVP, GEN. COUNSEL & CORP. SEC. sold 1,894 for 9.57, making the whole transaction’s value amount to 18,126. This particular insider is now the holder of 52,966 in total.

Marinus Pharmaceuticals Inc (MRNS) Earnings and Revenue Records

So, what does the last quarter earnings report of the company that was made public on 12/30/2023 suggests? It has posted -$0.74 earnings per share (EPS) not meeting the forecaster’s viewpoint (set at -$0.62) by -$0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year.

Marinus Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 10.11% and is forecasted to reach -1.87 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 20.00% through the next 5 years, which can be compared against the 6.04% growth it accomplished over the previous five years trading on the market.

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) Trading Performance Indicators

Let’s observe the current performance indicators for Marinus Pharmaceuticals Inc (MRNS). It’s Quick Ratio in the last reported quarter now stands at 4.01. The Stock has managed to achieve an average true range (ATR) of 0.54. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 15.34.

In the same vein, MRNS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.63, a figure that is expected to reach -0.63 in the next quarter, and analysts are predicting that it will be -1.87 at the market close of one year from today.

Technical Analysis of Marinus Pharmaceuticals Inc (MRNS)

[Marinus Pharmaceuticals Inc, MRNS] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 39.74% While, its Average True Range was 0.54.

Raw Stochastic average of Marinus Pharmaceuticals Inc (MRNS) in the period of the previous 100 days is set at 55.01%, which indicates a major rise in contrast to 23.85% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 42.33% that was lower than 54.99% volatility it exhibited in the past 100-days period.